In the study by Vernon et al. (2008), it was found that co-administration of the group III mGluR agonist L-AP4 and the group I mGluR5 antagonist MPEP provided an enhanced neuroprotection in the rat in vivo model of Parkinson’s disease. The gene discussed is GRM5; the disease is Parkinson disease.